NRx Pharmaceuticals increases at-the-market offering to $20M

NRx Pharmaceuticals, Inc., a Delaware-based pharmaceutical company, announced today an increase in the maximum aggregate offering price of its common stock to $20 million. This move is part of the company’s at-the-market (ATM) equity offering under an agreement with H.C. Wainwright & Co., LLC.

The company, trading on the Nasdaq Stock Market LLC under the ticker (NASDAQ:NRXP) for its common stock and NASDAQ:NRXPW for its warrants, amended its existing Offering Agreement dated August 14, 2023. The stock currently trades at $1.93, and analysis from InvestingPro indicates the stock is undervalued. Prior to this announcement, NRx Pharmaceuticals had sold approximately $1.8 million of its common stock under the agreement.

In conjunction with this increase, the company filed a prospectus supplement for an aggregate of $20 million. The legal opinion regarding the legality of the shares issuable under the Sales Agreement and covered by the Prospectus Supplement has been filed with the exhibits of the current report.

This announcement is based on a press release statement and follows the company’s compliance with the Securities Exchange Act of 1934. NRx Pharmaceuticals is known for its focus on the pharmaceutical preparations industry, with its principal executive offices located in Wilmington, Delaware.

The interim Chief Executive Officer, Jonathan Javitt, signed off on the report confirming the company’s actions on Thursday, April 17, 2025. The report provides investors and the market with updated information on the company’s financial maneuvers and its ongoing efforts to raise capital through the sale of common stock.

In other recent news, NRx Pharmaceuticals, Inc. has announced a significant $2.5 million investment from a global medical device manufacturer into its subsidiary, HOPE Therapeutics. This funding aims to support the acquisition of clinics specializing in treatments for severe depression and PTSD. In addition, HOPE Therapeutics has signed a definitive agreement to acquire Dura Medical (TASE:BLWV), which will expand its reach across Florida. This acquisition is expected to enhance HOPE’s service offerings, including Ketamine Therapy and Transcranial Magnetic Stimulation, and is contingent upon financial audits and regulatory approvals.

Furthermore, HOPE Therapeutics plans to acquire a majority stake in Neurospa TMS Holdings, LLC, which operates six clinics in Florida. This move is anticipated to boost HOPE’s revenue projections for 2025. In related developments, NRx Pharmaceuticals has filed a New Drug Application for NRX-100 and NRX-101, targeting treatments for suicidal depression and bipolar depression, respectively. BTIG has initiated coverage of NRx Pharmaceuticals with a Buy rating and a price target of $18, citing the company’s focus on addressing unmet needs in suicidal ideation and behavior.

Additionally, H.C. Wainwright has maintained a Buy rating on NRx Pharmaceuticals with a $19 price target, highlighting the company’s progress in drug applications and strategic clinic acquisitions. These developments underscore NRx Pharmaceuticals’ efforts to expand its therapeutic offerings and strengthen its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.